Peter Lundbäck1, Pernilla Stridh2, Lena Klevenvall3, Rosalind E Jenkins4, Marie Fischer1, Erik Sundberg3, Ulf Andersson3, Daniel J Antoine4, Helena Erlandsson Harris1. 1. 1 Department of Medicine, Rheumatology Unit, Karolinska Institutet , Stockholm, Sweden . 2. 2 Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet , Stockholm, Sweden . 3. 3 Department of Women's and Children's Health, Paediatric Unit, Karolinska Institutet , Stockholm, Sweden . 4. 4 MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Liverpool University , Liverpool, United Kingdom .
Abstract
AIMS: Pathogenic effects of the endogenous inflammatory mediator high mobility group box protein 1 (HMGB1) have been described in several inflammatory diseases. Recent reports have underlined the importance of post-translational modifications (PTMs) in determination of HMGB1 function and release mechanisms. We investigated the occurrence of PTMs of HMGB1 obtained from synovial fluid (SF) of juvenile idiopathic arthritis (JIA) patients. RESULTS: Analyses of 17 JIA patients confirmed high HMGB1 levels in SF. Liquid chromatography tandem mass-spectrometry (LC-MS/MS) analyses of PTMs revealed that total HMGB1 levels were not associated with increased lactate dehydrogenase activity but strongly correlated with nuclear location sequence 2 (NLS2) hyperacetylation, indicating active release of HMGB1. The correlation between total HMGB1 levels and NLS2 hypoacetylation suggests additional, acetylation-independent release mechanisms. Monomethylation of lysine 43 (K43), a proposed neutrophil-specific PTM, was strongly associated with high HMGB1 levels, implying that neutrophils are a source of released HMGB1. Analysis of cysteine redox isoforms, fully reduced HMGB1, disulfide HMGB1, and oxidized HMGB1, revealed that HMGB1 acts as both a chemotactic and a cytokine-inducing mediator. These properties were associated with actively released HMGB1. INNOVATION: This is the first report that characterizes HMGB1-specific PTMs during a chronic inflammatory condition. CONCLUSION: HMGB1 in SF from JIA patients is actively released through both acetylation-dependent and -nondependent manners. The presence of various functional HMGB1 redox isoforms confirms the complexity of their pathogenic role during chronic inflammation. Defining HMGB1 release pathways and redox isoforms is critical for the understanding of the contribution of HMGB1 during inflammatory processes.
AIMS: Pathogenic effects of the endogenous inflammatory mediator high mobility group box protein 1 (HMGB1) have been described in several inflammatory diseases. Recent reports have underlined the importance of post-translational modifications (PTMs) in determination of HMGB1 function and release mechanisms. We investigated the occurrence of PTMs of HMGB1 obtained from synovial fluid (SF) of juvenile idiopathic arthritis (JIA) patients. RESULTS: Analyses of 17 JIA patients confirmed high HMGB1 levels in SF. Liquid chromatography tandem mass-spectrometry (LC-MS/MS) analyses of PTMs revealed that total HMGB1 levels were not associated with increased lactate dehydrogenase activity but strongly correlated with nuclear location sequence 2 (NLS2) hyperacetylation, indicating active release of HMGB1. The correlation between total HMGB1 levels and NLS2 hypoacetylation suggests additional, acetylation-independent release mechanisms. Monomethylation of lysine 43 (K43), a proposed neutrophil-specific PTM, was strongly associated with high HMGB1 levels, implying that neutrophils are a source of released HMGB1. Analysis of cysteine redox isoforms, fully reduced HMGB1, disulfideHMGB1, and oxidized HMGB1, revealed that HMGB1 acts as both a chemotactic and a cytokine-inducing mediator. These properties were associated with actively released HMGB1. INNOVATION: This is the first report that characterizes HMGB1-specific PTMs during a chronic inflammatory condition. CONCLUSION:HMGB1 in SF from JIA patients is actively released through both acetylation-dependent and -nondependent manners. The presence of various functional HMGB1 redox isoforms confirms the complexity of their pathogenic role during chronic inflammation. Defining HMGB1 release pathways and redox isoforms is critical for the understanding of the contribution of HMGB1 during inflammatory processes.
Authors: R Kokkola; E Sundberg; A-K Ulfgren; K Palmblad; J Li; H Wang; L Ulloa; H Yang; X-J Yan; R Furie; N Chiorazzi; K J Tracey; U Andersson; H Erlandsson Harris Journal: Arthritis Rheum Date: 2002-10
Authors: Stefania Gardella; Cristina Andrei; Denise Ferrera; Lavinia V Lotti; Maria R Torrisi; Marco E Bianchi; Anna Rubartelli Journal: EMBO Rep Date: 2002-09-13 Impact factor: 8.807
Authors: Jianhua Li; Riikka Kokkola; Siamak Tabibzadeh; Runkuan Yang; Mahendar Ochani; Xiaoling Qiang; Helena E Harris; Christopher J Czura; Haichao Wang; Luis Ulloa; Hong Wang; H Shaw Warren; Lyle L Moldawer; Mitchell P Fink; Ulf Andersson; Kevin J Tracey; Huan Yang Journal: Mol Med Date: 2003 Jan-Feb Impact factor: 6.354
Authors: Alison V M Rodrigues; James L Maggs; Stephen J McWilliam; Munir Pirmohamed; Muireann Coen; Ian D Wilson; B Kevin Park; Daniel J Antoine Journal: Bioanalysis Date: 2014-04 Impact factor: 2.681
Authors: Bernardo L Rapoport; Helen C Steel; Annette J Theron; Liezl Heyman; Teresa Smit; Yastira Ramdas; Ronald Anderson Journal: Cells Date: 2020-07-10 Impact factor: 6.600
Authors: Man Sup Kwak; Hee Sue Kim; Khulan Lkhamsuren; Young Hun Kim; Myeong Gil Han; Jae Min Shin; In Ho Park; Woo Joong Rhee; Se Kyoung Lee; Sue Goo Rhee; Jeon-Soo Shin Journal: Redox Biol Date: 2019-04-15 Impact factor: 11.799